Core Viewpoint - Cosmos Health Inc. has appointed Dr. Dimitrios Iliopoulos to its Advisory Board to enhance its biotechnology initiatives, particularly in AI-driven drug discovery and clinical-stage therapeutic development [1][7]. Group 1: Appointment and Expertise - Dr. Iliopoulos is a recognized expert in artificial intelligence, drug discovery, and drug development, currently serving as Co-Founder and CEO of Athos Therapeutics Inc., which focuses on precision therapeutics for autoimmune diseases [2]. - He has a strong academic background, having served as an Assistant Professor at Harvard Medical School and a tenured Associate Professor at UCLA, where he founded the UCLA Center for Systems Biomedicine [3]. - Dr. Iliopoulos has received numerous awards for his contributions to drug development and has published over 130 peer-reviewed articles, with more than 24,000 citations [4]. Group 2: Contributions to Drug Discovery - He has developed innovative AI-enabled strategies that have accelerated drug discovery in oncology and autoimmune diseases, including the identification of metformin's anti-cancer properties [5]. - His research at UCLA led to the identification of miR-124 as a key target for ulcerative colitis, contributing to clinical development programs in inflammatory bowel disease [5]. Group 3: Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands [8]. - The company manufactures pharmaceuticals and other health products through its subsidiary, Cana Laboratories S.A., which is certified by the European Medicines Agency [8]. - Cosmos Health is expanding its R&D initiatives targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [9].